ptcl

Pakistan's National Carrier PTCL Integrates Avaya With Its Digital Education Platform, QTaleem

Retrieved on: 
Monday, December 7, 2020
Telecommunications, Companies, ptcl, Avaya

Avaya Spaces innovation is enabling school administrators, teachers and students to deliver a 360-degree digital education experience.

Key Points: 
  • Avaya Spaces innovation is enabling school administrators, teachers and students to deliver a 360-degree digital education experience.
  • DUBAI, UAE, Dec. 7, 2020 /PRNewswire/ -- GITEX Technology Week: Pakistan Telecommunication Company Limited (PTCL), one of the leading telecom and ICT services providers in Pakistan, has partnered with Avaya (NYSE: AVYA) on QTaleem, an online digital learning education platform and part of the PTCL Education Cloud solution offering.
  • Launching nationwide, PTCL QTaleem delivers a 360-degree digital education experience, enabling school administrators, teachers and students to be as productive online as they are on-campus.
  • Avaya Spaces, the all-in-one video collaboration app for the digital workplace, integrates with PTCL's QTaleem and enables the delivery of seamless video classes.

Pakistan's National Carrier PTCL Integrates Avaya With Its Digital Education Platform, QTaleem

Retrieved on: 
Monday, December 7, 2020
Telecommunications, ptcl, Companies, Avaya

DUBAI, UAE, Dec. 7, 2020 /PRNewswire/ -- GITEX Technology Week: Pakistan Telecommunication Company Limited (PTCL), one of the leading telecom and ICT services providers in Pakistan, has partnered with Avaya (NYSE: AVYA) on QTaleem, an online digital learning education platform and part of the PTCL Education Cloud solution offering.

Key Points: 
  • DUBAI, UAE, Dec. 7, 2020 /PRNewswire/ -- GITEX Technology Week: Pakistan Telecommunication Company Limited (PTCL), one of the leading telecom and ICT services providers in Pakistan, has partnered with Avaya (NYSE: AVYA) on QTaleem, an online digital learning education platform and part of the PTCL Education Cloud solution offering.
  • Launching nationwide, PTCL QTaleem delivers a 360-degree digital education experience, enabling school administrators, teachers and students to be as productive online as they are on-campus.
  • Speaking on the partnership, Zarrar Hasham Khan, Chief Business Services Officer, PTCL, said, "As a national carrier, PTCL is enabling an online education framework that has the potential to help more than 53 million students across the country.
  • Avaya Spaces, the all-in-one video collaboration app for the digital workplace, integrates with PTCL's QTaleem and enables the delivery of seamless video classes.

Peripheral T-Cell Lymphoma (PTCL) Market and Epidemiology Forecast, 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 30, 2020
Professional services, Consulting, Non-Hodgkin lymphoma, Chemistry, Physical sciences, Drugs, Antineoplastic drugs, Astellas Pharma, Depsipeptides, Prodrugs, Romidepsin, ptcl, Brentuximab vedotin, Lymphoma

The "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The PTCL market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM PTCL market size from 2017 to 2030.
  • The drug candidate is in Phase II stage of development for Peripheral T-cell lymphoma (PTCL) in Japan.
  • Adcetris and Istodax (Romidepsin) for the first line treatment of PTCL is projected to lead the market with the highest market share in 2030.

Pakistan Telecommunication Company Limited deploys Nokia software products to enhance customer experience and service

Retrieved on: 
Wednesday, June 10, 2020
Companies, Telecommunications, ptcl, Nokia, Customer service, Islamabad Capital Territory, ptcl

Islamabad, Pakistan Pakistan Telecommunication Company Limited (PTCL) has deployed Nokia automation, analytics and machine learning software to enhance the customer experience and improve customer service accuracy and efficiency.

Key Points: 
  • Islamabad, Pakistan Pakistan Telecommunication Company Limited (PTCL) has deployed Nokia automation, analytics and machine learning software to enhance the customer experience and improve customer service accuracy and efficiency.
  • PTCL customers can now enjoy a better overall experience as Nokia SMP constantly improves trouble prediction and resolution capability, while reducing customer service costs.
  • Henrique Vale, Head of Nokia Software for MEA, said, "This go-live deployment provides several efficient tools that enhance PTCLs customer service capabilities and the user experience across the board.
  • Pakistan Telecommunication Company Limited (PTCL) is the largest integrated Information Communication Technology (ICT) Company of Pakistan.

Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell Lymphoma

Retrieved on: 
Tuesday, September 17, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, ptcl, Economy of Pakistan

(TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter Solasia), a specialty pharmaceutical company based in Asia, today announced that patient registration reached the target number of cases for the darinaparsin Phase 2 study.

Key Points: 
  • (TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter Solasia), a specialty pharmaceutical company based in Asia, today announced that patient registration reached the target number of cases for the darinaparsin Phase 2 study.
  • This study is a pivotal (final) study for PTCL based on prior consultation with the authority.
  • In a US Phase 2 study, darinaparsin demonstrated evidence of clinical activity in lymphoma, in particular PTCL.
  • Furthermore, the Phase 1 study done in US, and the Pan-Asian Phase 1 study both demonstrated positive efficacy and safety.

Global Peripheral T-Cell Lymphoma (PTCL) Market to 2026 - Celgene Leads Industry Sponsors with the Highest Number of Clinical Trials, Followed by Spectrum Pharmaceuticals

Retrieved on: 
Wednesday, June 19, 2019
Health, Life sciences, Bristol-Myers Squibb, Celgene, Summit, New Jersey, Spectrum Pharmaceuticals, ptcl, Clinical trial, Draft:HDAC inhibitors in cancer treatment

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Peripheral T-Cell Lymphoma (PTCL)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 19, 2019 /PRNewswire/ -- The "Market Spotlight: Peripheral T-Cell Lymphoma (PTCL)" report has been added to ResearchAndMarkets.com's offering.
  • The majority of industry-sponsored drugs in active clinical development for PTCL are in Phase II, with only one drug in Phase III.
  • Celgene has the highest number of completed clinical trials for PTCL, with nine trials.
  • Celgene leads industry sponsors with the highest number of clinical trials for PTCL, followed by Spectrum Pharmaceuticals.

Global Peripheral T-Cell Lymphoma (PTCL) Market Spotlight 2018-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 19, 2019
Health, Oncology, Pharmaceutical, Health, Articles, RTT, Spectrum Pharmaceuticals, ptcl, Celgene, Pharmaceutical industry, Lymphoma, Peripheral T-cell lymphoma not otherwise specified, Subcutaneous T-cell lymphoma

The "Market Spotlight: Peripheral T-Cell Lymphoma (PTCL)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Peripheral T-Cell Lymphoma (PTCL)" report has been added to ResearchAndMarkets.com's offering.
  • The approved drugs in the PTCL space focus on a wide variety of targets.
  • The majority of industry-sponsored drugs in active clinical development for PTCL are in Phase II, with only one drug in Phase III.
  • Celgene leads industry sponsors with the highest number of clinical trials for PTCL, followed by Spectrum Pharmaceuticals.

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2019
Health, Oncology, Pharmaceutical, Non-Hodgkin lymphoma, Medical specialties, Lymphoma, Peripheral T-cell lymphoma, ptcl, T-cell lymphoma, Anatomy, Medicine, Peripheral T-cell lymphoma not otherwise specified, Subcutaneous T-cell lymphoma

The "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Peripheral T-Cell Lymphomas (PTCL) development.
  • clinical, pre-clinical and discovery stages for Peripheral T-Cell Lymphomas (PTCL)
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Peripheral T-Cell Lymphomas (PTCL)
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
    2.
  • Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2019 Overview
    An Overview of Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2019

Peripheral T-Cell Lymphomas (PTCL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 22, 2019
Health, Pharmaceutical, Non-Hodgkin lymphoma, Peripheral T-cell lymphoma, Lymphoma, ptcl, T-cell lymphoma, Anatomy, Medicine, Economy of Pakistan, Peripheral T-cell lymphoma not otherwise specified, Subcutaneous T-cell lymphoma

The "Peripheral T-Cell Lymphomas (PTCL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral T-Cell Lymphomas (PTCL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.
  • Coverage of API manufacturers for Peripheral T-Cell Lymphomas (PTCL) marketed products spanning across United States, Europe, China and India.
  • This report provides a comprehensive understanding of the emerging Phase III therapies for Peripheral T-Cell Lymphomas (PTCL) which can turn out to be future prospective competitors for the marketed products.